TEVA:NYE-Teva Pharmaceutical Industries Limited (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NYE

Last Closing Price

USD 7.56

Change

-0.34 (-4.30)%

Market Cap

USD 8.75B

Volume

0.02B

Average Target Price

USD 11.27 (+49.03%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-27 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ZTS Zoetis Inc

-6.14 (-5.21%)

USD53.08B 35.94 21.76
CTLT Catalent, Inc

-1.51 (-2.99%)

USD7.87B 60.32 18.28
ELAN Elanco Animal Health Incorpora..

+0.40 (+1.87%)

USD7.82B 119.00 16.03
RDY Dr. Reddy's Laboratories Limit..

-1.78 (-4.41%)

USD6.32B 28.75 N/A
PRGO Perrigo Company plc

-0.44 (-0.95%)

USD5.75B 39.50 10.56
BHC Bausch Health Companies Inc

-0.93 (-6.02%)

USD5.36B N/A 8.38
CGC Canopy Growth Corporation

-0.57 (-3.76%)

USD4.34B N/A N/A
AMRX Amneal Pharmaceuticals, Inc

-0.45 (-13.04%)

USD1.11B N/A 12.38
ACB Aurora Cannabis Inc

+0.13 (+13.81%)

USD0.79B 3.16 N/A
APHA Aphria Inc

-0.03 (-0.90%)

USD0.67B 8.50 N/A

ETFs Containing TEVA

Symbol Name Weight Mer Price(Change) Market Cap
GNRX VanEck Vectors Generic Dr.. 4.81 % 0.55 %

N/A

USD3.35M
IDEV iShares Core MSCI Interna.. 0.07 % 0.05 %

-1.35 (-3.00%)

USD2.03B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.86% 59% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.86% 59% F 57% F
Trailing 12 Months  
Capital Gain -51.48% 50% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.48% 50% F 16% F
Trailing 5 Years  
Capital Gain -87.80% 43% F 7% F
Dividend Return 4.45% 75% C 16% F
Total Return -83.35% 43% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain -31.39% 24% F 2% F
Dividend Return 1.12% 80% B- 27% F
Total Return -30.28% 24% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 30.62% 35% F 18% F
Risk Adjusted Return -98.89% 24% F 3% F
Market Capitalization 8.75B 94% A 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 457.10 10% F 1% F
Price/Book Ratio 0.62 75% C 72% C-
Price / Cash Flow Ratio 11.69 44% F 25% F
EV/EBITDA 7.92 64% D 53% F
Management Effectiveness  
Return on Equity -6.49% 59% F 17% F
Return on Invested Capital 7.09% 67% D+ 56% F
Return on Assets 2.87% 76% C 55% F
Debt to Equity Ratio 175.79% 40% F 18% F
Technical Ratios  
Short Ratio 1.44 83% B 60% D-
Short Percent N/A N/A N/A N/A N/A
Beta 1.58 47% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.